Medullary thyroid cancer (MTC) represents 3% of all clinical thyroid cancers and arises from
thyroid C cells that produce calcitonin. Locally advanced or metastatic MTC requires a …

Background Medullary thyroid cancer (MTC) accounts for approximately 1.6% of new cases
of thyroid cancer. The objective of this study was to describe patient characteristics …

Opinion statement Medullary thyroid carcinoma (MTC) is a neuroendocrine malignancy that
occurs in hereditary (25%) and sporadic (75%) clinical settings. MTC is present in all …

There have been several recent advances in the molecular biology, diagnosis, imaging, and
treatment options for MTC. Downstaging and treating metastatic disease more effectively …

Medullary thyroid carcinoma (MTC) is a prototype disease in the rapidly emerging field of
molecular endocrine oncology. Since its recognition in 1959, MTC has distinguished itself …

Recent advances in the diagnosis and treatment of medullary thyroid carcinoma (MTC) have
been significant, but some issues remain controversial. MTC may occur either as a …

Medullary thyroid carcinoma (MTC) is a rare calcitonin‐producing neuroendocrine tumour
that originates from the parafollicular C‐cells of the thyroid gland. The RET proto‐oncogene …

This article summarizes the major clinical, pathological, and molecular features of medullary
thyroid carcinoma (MTC), based on a review of the most significant advances in our …

Medullary thyroid cancer (MTC) is a rare tumor arising from the calcitonin-producing
parafollicular C cells of the thyroid gland, occurring either sporadically or alternatively in a …

Parafollicular C‐cell‐derived medullary thyroid cancer (MTC) comprises 3% to 4% of all
thyroid cancers. While cytotoxic treatments have been shown to have limited efficacy …